NOVARTIS for NOVARTIS
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Free Trade Agreements: - Intellectual Property Provisions - Free Trade Agreements Access to Medicines Global Health IssuesIndia IP Trans-Pacific Partnership FTA Sub-standards Medicines Quality of Medicines
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID DRAKE | — |
| SARAH HALLER | — |
| SHAWN O'NEAIL | — |
Taxation/Internal Revenue Code TAX
S1128 Preserving Access to Orphan Drugs Act of 2013 H.R.2315 Preserving Access to Orphan Drugs Act of 2013
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| DAVID DRAKE | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
Medicare/Medicaid MMM
Access to Life Saving Medicines Act Provide Medicare Part B Coverage for Vaccines Covered under Part D Medicaid Coverage of Vaccines
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| DAVID DRAKE | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
Health Issues HCR
Gene Therapy Personalized Medicine Section 9008 of Patient Protection and Affordable Care Act Dextromethorphan - Age Restrictions - Controlling bulk shipments - PACT ActFSA/HSA - Support reinstating coverage of OTC products HR 351/S 351 - Medicine Decisions Act of 2011 (IPAB) 340B Drug Discount Program Dual Eligibles Program DQSA Implementation (Track & Trace) Certified Importer Program MDUFA (Medical Device User Fee Act) Implementation Medical Device Tax Repeal Drug Importation Limitations on lawful use of caffeine Reimbursement for medical devices GMP related to manufacturing sites Federal BTC and GMO labeling laws
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| DAVID DRAKE | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
Budget/Appropriations BUD
Pandemic Influenza Funding FDA Appropriations funding for Generic Drugs Certified Importer Program (CIP) FY 2013 - Labor HHS Appropriations Bill - FY 2014 Labor HHS Appropriations Bill
Foreign entity interest: Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL CASSERLY | — |
| DAVID DRAKE | — |
| SARAH HALLER | — |
| BRENDA J LUCKRITZ | — |
| SHAWN O'NEAIL | — |
| KATHERINE SOLON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.